TY - JOUR
T1 - Autophagy
T2 - Friend or foe in lung disease?
AU - Mizumura, Kenji
AU - Cloonan, Suzanne
AU - Choi, Mary E.
AU - Hashimoto, Shu
AU - Nakahira, Kiichi
AU - Ryter, Stefan W.
AU - Choi, Augustine M.K.
N1 - Publisher Copyright:
Copyright © 2016 by the American Thoracic Society.
PY - 2016/3
Y1 - 2016/3
N2 - Autophagy is a highly conserved process by which cells can recycle organelles and proteins by degrading them in the lysosomes. Although autophagy is considered a dynamic system responsible for cellular renovation and homeostasis under physiological conditions, it is increasingly clear that autophagy is directly relevant to clinical disease. During disease progression, autophagy not only serves as a cellular protective mechanism but also can represent a harmful event under certain conditions. In addition, although autophagy can act as a nonselective bulk degradation process, recent research shows that autophagy can selectively degrade specific proteins, organelles, and invading bacteria, in processes termed "selective autophagy." Selective autophagy has drawn the attention of researchers because of its potential importance in clinical diseases. In this article, we outline the most recent studies implicating autophagy and selective autophagy in human lung diseases, including chronic obstructive pulmonary disease, pulmonary hypertension, idiopathic pulmonary fibrosis, and sepsis. We also discuss the relationship between autophagy and other molecular mechanisms related to disease progression, including programmed necrosis (necroptosis) and the inflammasome, an inflammatory signaling platform that regulates the secretion of IL-1b and IL-18. Finally, we examine the dual nature of autophagy and selective autophagy in the lung, which have both protective and injurious effects for human lung disease.
AB - Autophagy is a highly conserved process by which cells can recycle organelles and proteins by degrading them in the lysosomes. Although autophagy is considered a dynamic system responsible for cellular renovation and homeostasis under physiological conditions, it is increasingly clear that autophagy is directly relevant to clinical disease. During disease progression, autophagy not only serves as a cellular protective mechanism but also can represent a harmful event under certain conditions. In addition, although autophagy can act as a nonselective bulk degradation process, recent research shows that autophagy can selectively degrade specific proteins, organelles, and invading bacteria, in processes termed "selective autophagy." Selective autophagy has drawn the attention of researchers because of its potential importance in clinical diseases. In this article, we outline the most recent studies implicating autophagy and selective autophagy in human lung diseases, including chronic obstructive pulmonary disease, pulmonary hypertension, idiopathic pulmonary fibrosis, and sepsis. We also discuss the relationship between autophagy and other molecular mechanisms related to disease progression, including programmed necrosis (necroptosis) and the inflammasome, an inflammatory signaling platform that regulates the secretion of IL-1b and IL-18. Finally, we examine the dual nature of autophagy and selective autophagy in the lung, which have both protective and injurious effects for human lung disease.
KW - Autophagy
KW - Ciliophagy
KW - Inflammasome
KW - Mitophagy
KW - Necroptosis
UR - http://www.scopus.com/inward/record.url?scp=84964262410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964262410&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201507-450MG
DO - 10.1513/AnnalsATS.201507-450MG
M3 - Article
C2 - 27027951
AN - SCOPUS:84964262410
SN - 2325-6621
VL - 13
SP - S40-S47
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
ER -